Status:
COMPLETED
The Use of Angiotensin Receptor Blockers and the Risk of Cancer
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Neoplasm
Eligibility:
All Genders
Brief Summary
The primary objective of this study was to assess whether angiotensin blockers (ARBs) and telmisartan in particular, are associated with an increased overall risk of the four most common cancers, name...
Eligibility Criteria
Inclusion
- Patients prescribed an antihypertensive agent between 01-JAN-1995 and 31-DEC-2008 with at least two years of up-to-standard medical history in United Kingdom's General Practice Research Database (GPRD)
Exclusion
- History of cancer at any time prior to cohort entry
Key Trial Info
Start Date :
February 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1165781 Patients enrolled
Trial Details
Trial ID
NCT02215733
Start Date
February 1 2011
Last Update
August 13 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.